Auna entered this earnings report with a hot stock and a cold reputation on profitability. The shares are up about 24% over the past three months, yet they barely moved after the release, closing at $5.43, only 0.2% above the prior close. That muted reaction contrasts with a healthcare provider reporting Q2 revenue of PEN 1,238.2m and Basic EPS of PEN 0.40, while trailing net profit margin over the past year is only 0.3% with weak interest coverage.

Love the revenue scale Auna is putting up but worried about thin margins and weak interest coverage? You can compare this setup with companies on our 77 resilient stocks with low risk scores.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): PEN 1,238.17m vs. PEN 1,093.94m (higher revenue level year on year)
• Net Income (Excl. Extra Items) (Q2 2026 vs Q2 2025): PEN 29.43m vs. PEN 81.98m (lower net income year on year)
• Basic EPS (Q2 2026 vs Q2 2025): PEN 0.40 vs. PEN 1.11 (lower earnings per share year on year)
• Trailing 12-Month Net Profit Margin (Q2 2026 vs prior year): 0.3% vs. 5.5% (margin compression over the last year)

Tired of scrolling through dense earnings tables and margin figures trying to make sense of Auna's story? Get a clear, visual view of Auna's financial health, including balance sheet strength and debt coverage, in the full company report for Auna.

Auna’s Growth Story Meets Mixed Profit Milestones

Bulls argue that Auna can turn its expanding Latin American healthcare network and high complexity services into a step change in margins while keeping growth on track. Q2 results partly support that view. Revenue grew 9% on an FX neutral basis with Mexico, Peru and Colombia all contributing, and high complexity oncology volumes in Mexico rose sharply, which lines up with the thesis that more complex care can deepen patient relationships and raise revenue per visit.

However, the bullish claim hinges on margin lift rather than just more activity. Here, the data are less supportive. Consolidated adjusted EBITDA declined 9% FX neutral, and each country reported weaker year on year EBITDA despite higher revenue. Management reaffirmed 2026 guidance and highlighted improving capacity utilization and stable medical loss ratios, which suggests pieces of the model are working, but the margin inflection that bulls look for is not yet visible in the reported numbers.

Compare Auna’s on the ground progress in Mexico, Peru and Colombia with what the street is actually pricing in. See the consensus price target analysis for Auna to judge whether analysts think this operational momentum lines up with the current share price.

Auna Bears See Margins Blinking Red, Not Just Yet

The bearish view is clear. Auna is growing into new regions while margins and cash generation risk falling behind. Q2 does give bears ammunition. Adjusted EBITDA fell 9% on an FX neutral basis even though revenue rose 9%, and all three countries reported weaker year on year EBITDA. That matches worries about execution, onboarding costs and complexity eating into profitability.

At the same time, some of the darkest fears are not fully playing out. Collections in Colombia improved with intervened payors now a smaller slice of revenue, while risk sharing contracts rose to 24%. Mexico showed sequential EBITDA and procedure growth, which points to at least some utilization recovery. Leverage eased to 3.6x with stronger free cash flow. Overall, Q2 misses key margin improvement milestones that would quiet the bearish narrative, but it does not show the business stalling or the balance sheet straining.

After a quarter where margins compressed to 0.3% and interest coverage looks thin, it is worth asking whether these are isolated growing pains or signs of deeper structural pressure inside Auna. Review the independent risk analysis for Auna which shows 3 important warning signs to see if the weak coverage and one off items are just the start of a broader risk story.

Own Your Next Investing Move

If Auna’s mix of strong revenue scale and thin margins has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch for an entry point that fits your risk and return goals. Once you are invested, keep a clear view of your positions with the Portfolio Command Center that filters out noise and focuses on the most important updates for your holdings. For longer term context, tap into thousands of investor viewpoints through the Community to see how others are thinking about catalysts and risks. By spotting potential shifts in Auna’s story early, you may be able to identify key catalysts and avoid hidden risks before the wider market reacts.

Seeking Alternatives Beyond Auna Stock

Fresh stock ideas can move from quiet to flying once momentum builds. Use these under the radar for now screeners before the crowd catches on and act now.

• Spot early breakouts in overlooked sectors by scanning curated companies in the 19 high quality undiscovered gems so you are not chasing stocks after they have already moved.
• Capture steady income while prices are still reasonable by checking companies in the 12 dividend fortresses before yields compress and the best options get picked over.
• Ride long term themes behind critical materials by reviewing producers in the 28 best rare earth metal stocks while they are still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.